This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	REV1 homolog (REV1); REV3-like catalytic subunit of DNA polymerase- ζ (REV3L)	<p>Mouse studies suggest that inhibitors of REV1 or REV3L could help increase the efficacy of chemotherapeutics to treat cancer. In a mouse model of Burkitt's lymphoma, Rev1-depleted tumors showed greater sensitivity to cisplatin and developed less resistance to cyclophosphamide than control tumors. In a mouse model of cisplatin-resistant lung cancer, Rev3-depleted tumor transplants had greater sensitivity to cisplatin than control transplants. Next steps include developing small molecule and RNAi inhibitors of REV1 and REV3L.</p> <p>SciBX 3(47); doi:10.1038/scibx.2010.1408 Published online Dec. 9, 2010</p>	Patent and licensing status undisclosed	<p>Doles, J. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Nov. 5, 2010; doi:10.1073/pnas.1011409107 Contact: Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: hemann@mit.edu</p> <p>Xie, K. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Nov. 5, 2010; doi:10.1073/pnas.1011412107 Contact: Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: hemann@mit.edu Contact: Graham C. Walker, same affiliation as above e-mail: gwalker@mit.edu</p>